Achillion Pharmaceuticals Inc 

ACHN:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
7.77 0.21   2.78%0.00%823,358675.6K

Market data is delayed by at least 20 minutes.
Market is closed. As of 03:59 PM ET 5/17/2013
 
 
 

Latest News Headlines for Achillion Pharmaceuticals Inc

Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team
3 days 3 hours 53 minutes ago - GlobeNewsWire via Dow Jones News
Achillion Appoints Dr. David Apelian as Chief Medical Officer and Expands Clinical Operations Team NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV.
Achillion to Present at Three Upcoming Investor Conferences
9 days 3 hours 53 minutes ago - GlobeNewsWire via Dow Jones News
Achillion to Present at Three Upcoming Investor Conferences NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences:
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 20, 2013
This report contains detailed information about the company's business finances and management.
10-Q
May 7, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
7.60
Previous Close
7.56
Day High
7.815
Day Low
7.56
52wk High/Date
11.36 / 10/16/2012
52wk Low/Date
5.42 / 8/10/2012
% off 52wk High
-31.60%
% off 52wk Low
43.36%
Beta (5 Yr)
0.7
Market Capitalization
750.2M
Shares Outstanding
96.6M
Volatility Avg
55.51
EPS(TTM)
-0.64
P/E Ratio
Not Meaningful
Dividend Announcement
--
Dividend Yield
0.00%
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 5/17/2013 4:00 PM ET
 
 
 

ACHN Achillion Pharmaceuticals Inc vs. Peers

Peers 
ACHN
Achillion Pharmaceuticals Inc
-3.00%
Pfizer Inc.
15.47%
Johnson & Johnson
25.66%
Merck & Co., Inc.
12.34%
ACHN
Achillion Pharmaceuticals Inc
0.00%
Pfizer Inc.
3.31%
Johnson & Johnson
3.00%
Merck & Co., Inc.
3.74%
ACHN
Achillion Pharmaceuticals Inc
2.78%
Pfizer Inc.
-0.99%
Johnson & Johnson
0.73%
Merck & Co., Inc.
-0.82%
Compare these stocks